According to the recent report by Future Market Insights (FMI), the small-scale bioreactors market size is estimated to stand at USD 7.71 billion by 2033. Over the forecast period, the market is assessed to trail at a CAGR of 14.8%. For the year 2023, FMI has estimated the market to be worth USD 1.94 billion.
Salient Market Propellers
Accelerating Move Toward Single-use Bioreactors
With the support of sufficient funds, the active players in the market are expected to tap into new opportunities to grow further. Currently, companies are concentrating on commercializing their portfolio of single-use bioreactors and outsourced process design services.
This is further supported by the increasing demand for premium quality and improved efficacy in drug manufacturing. As a result, the biopharmaceutical industry is rapidly shifting toward the deployment of single-use bioprocessing systems.
These systems are incorporated with real-time monitoring and technological system that facilitates automation, improve data-driven quality control, and propel driving performance. Thus, it is predicted that the move toward advanced bioprocessing technology devices, like small-scale bioreactor devices, boost the market growth.
| Attributes | Details |
|---|---|
| Small-scale Bioreactors Market Value (2023) | USD 1.94 billion |
| Small-scale Bioreactors Market Forecast Value (2033) | USD 7.71 billion |
| Small-scale Bioreactors Market CAGR (2023 to 2033) | 14.8% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The market generated a revenue of USD 1.69 billion in 2022. Looking forward, the market is set to register a CAGR of 14.8% to reach USD 1.94 billion in 2023. By 2033 end, the market is anticipated to reach a market valuation of USD 7.71 billion.
In the preceding years, especially 2020 and 2021, the market growth was marked by significant expansions of facilities. In order to carry out research and development for COVID-19 vaccines. The forecast period is going to witness more opportunities for the market to expand. Some common factors that are expected to positively influence the market include:
| Duration | Market Analysis |
|---|---|
| Short-term Growth | The market is anticipated to stand at a valuation of USD 2.56 billion by 2025. The scope of small-scale bioreactors’ businesses has expanded post the COVID-19 outbreak. As governments across the globe have understood the importance of responsive infrastructure for vaccine manufacturing. This can be effectively achieved by the deployment of a small-scale production bioreactor that enables more robust and versatile production. |
| Mid-term Growth | By 2028 end, the market is estimated to surpass a market worth of USD 3.87 billion. The mid-term growth of the market is expected to be defined by the growing focus on sustainability. Generally, small-scale bioreactors are more environment-friendly than their traditional counterparts. This makes small-scale bioreactors an attractive option for firms looking to reduce their carbon footprint. |
| Long-term Growth | The market is projected to amass a total of USD 7.71 billion by 2033. In the course of the next 10 years, small-scale bioreactors’ businesses are predicted to direct their focus toward patient-centric healthcare. Since these systems are capable of producing customized therapies, tailored to individual patients, the demand for them is anticipated to rise. Additionally, the small-scale bioreactors are expected to prove themselves to be instrumental in decentralized manufacturing. As these bioreactors are expected to become common, the pharmaceutical industry is predicted to lessen its dependency on centralized manufacturing facilities. |
The size of the bioreactor that can hold the capacity of 1L to 3L registered a significant market share exceeding 31% of the entire revenue in 2022. Over the forecast period, the segment is expected to trail at a robust pace to maintain its dominant position. The rapid growth of the segment can be attributed to the extensive availability of bioreactors with a volume capacity of 1L to 3L. Owing to the several benefits of these bioreactors in laboratories, numerous players also provide these products.
These bioreactors further allow the evaluation of various experiments and parallel processing, while keeping the properties of a larger-scale bioreactor intact. Consequently, the demand for these bioreactors is anticipated to significantly expand over the upcoming years.
Following 1L–3L segment, the bioreactors having 3L–5L capacity are anticipated to hold a second position, in terms of CAGR, over the forecast period. Systems with this much capacity offer several benefits for the research and development of fermentation process development systems. Some of these benefits include reduced infrastructure, increased size and turnaround flexibility, quick system implementation, and negligible maintenance requirement.
The CROs and CMOs segment clinched the maximum share of 45.8% in the year 2022. The segment is anticipated to assume a strong CAGR over the next decade to retain its leading position in the forecast period. CROs and CMOs are incessantly looking out for enhanced single-use systems for their clients to better their service offerings.
Consequently, these companies are adopting novel single-use bioreactors more rapidly than therapeutic manufacturers. This can be attributed to the fact that CROs and CMOs persist in their competency when they develop biologics more affordably and successfully. This can be particularly witnessed in clinical trials and research and development.
The academic and research institutes segment is assessed to witness significant growth in the forecast period. This can be credited to the widespread adoption of small-scale bioreactors for various procedures in academic and research institutes. Additionally, the vigorous support from various governments and significant funding for research activities available in developed countries are augmenting segment growth.
In August 2022, for instance, the University of California received more than USD 1.07 billion for external research funding. In addition to this, the deep market penetration of small-scale bioreactors in reputable academic institutions is expected to propel segment growth.
The reusable bioreactors segment led the market in 2022 and held the maximum market share of more than 80.05% over the forecast period. This can be ascribed to the increasing demand for reusable bioreactors in biopharmaceuticals and pharmaceuticals. Owing to the ability of reusable bioreactors to develop greater quantities of products. The reusable bioreactor has various other benefits like reduced costs, versatile accessory configuration, a prolonged lifespan, and simple handling. Owing to the aforementioned benefits, the segment has enjoyed high market penetration.
The product segment of single-use bioreactors is estimated to experience rapid CAGR over the next decade. This can be attributed to their frequent use in novel biotech processes. The main reasons behind their frequent use include exceptional quality to enhance flexibility, reduce operational expenses, and lower investment. Such benefits of single-use products over other small-scale bioreactors are projected to propel the segment expansion.
The United States small-scale bioreactors market amassed a dominant market share in 2022. This is grounded in the fact that key players are widely available in the United States for the production of single-use and small-scale bioreactors. The market is also witnessing heightened investments in biopharmaceutical research. This is a consequence of rising incidences of chronic disorders, heightened demand for new biologic drugs, and advanced equipment such as small-scale bioreactors.
In January 2022, for instance, Erbi Biosystems, which is a developer of cutting-edge, automatic, compact, and high-performing cell culture systems, completed a USD 4 million funding round. With the recent round of funding, the company has been planning to enhance its operations to catch up with the surging sales of Breez perfusion bioreactor. In order to make modifications to enhance cell therapy applications.
The China market is assessed to expand at a robust CAGR over the stipulated time frame. Regional growth is driven by robustly transforming biotechnological industries and economies. Some top players are further expanding their operations in emerging economies of Asia like China to support increasing pharmaceutical and biotech markets in the region. These factors are projected to bolster growth in China.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The small-scale bioreactors market is extremely competitive, with top players holding the maximum share of the market. Companies are constantly employing different strategies like the release of innovative products. Additionally, mergers and acquisitions, partnerships and collaborations to maintain their market presence.
In October 2021, for instance, Thermo Fisher Scientific partnered with 3M to enhance process efficacy and diversity in commercial therapeutic manufacturing. This is made possible by uniting Harvest RC Chromatographic Clarifier of 3M and HyPerforma Single-Use Bioreactor Systems of Thermo Scientific.
The growing expansion of established companies in developing economies is also propelling market growth. In January 2022, for instance, H.E.L Group a multinational manufacturer and developer of cutting-edge laboratory tools for process optimization and safety extended its operations in India. With this expansion, the company aims to strongly emphasize the rapid development of biotech industries.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD billion for Value |
| Key Regions Covered | North America; Europe; Asia Pacific; Latin America; The Middle East and Africa |
| Key Countries Covered | The United States, Canada, Germany, the United Kingdom, France, Italy, NORDICS, Spain, Russia, Poland, BENELUX, China, Japan, India, ASEAN, Oceania, South Korea, Brazil, Mexico, Argentina, GCC Countries, South Africa, Northern Africa, Türkiye |
| Key Segments Covered | Product, Capacity, End User, and Region |
| Key Companies Profiled | Sartorius AG; Thermo Fisher Scientific Inc.; Merck KGaA; Danaher Corporation; Lonza Group; Eppendorf AG; Miltenyi Biotec; Getinge AB; Solaris Biotechnology Srl; Infors AG |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is valued at USD 1.94 billion in 2023.
The market is estimated to secure a valuation of USD 7.71 billion in 2033.
Through 2033, the market is projected to continue to expand at a CAGR of 14.8%.
CROs and CMOs to experience a staggering market share of 45.8%.
Strengthening the emphasis on healthcare that is patient-focused to create more opportunities.
| Market Value for 2024 | USD 10,707.6 million |
|---|---|
| Projected Market Value for 2034 | USD 20,289.1 million |
| Value-based CAGR (2024 to 2034) | 6.60% |
| Market Size (2022) | USD 13.1 Billion |
|---|---|
| Market Size (2032) | USD 119.3 Billion |
| Market CAGR (2022 to 2032) | 24.9% |
Explore Life Science & Biotechnology Insights
View Reports
Small-scale Bioreactors Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
